{"id":143,"date":"2021-04-28T13:51:50","date_gmt":"2021-04-28T04:51:50","guid":{"rendered":"http:\/\/new21.genomeopinion.com:8088\/wordpress\/?post_type=team&#038;p=143"},"modified":"2024-12-12T16:49:29","modified_gmt":"2024-12-12T07:49:29","slug":"%ea%b3%a0%ec%98%81%ec%9d%bc","status":"publish","type":"team","link":"https:\/\/en.nobomedicine.com\/?team=%ea%b3%a0%ec%98%81%ec%9d%bc","title":{"rendered":"Youngil Koh, MD \/ PHD"},"content":{"rendered":"\n<div style=\"height:134px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile is-vertically-aligned-top has-black-color has-text-color\"><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"683\" height=\"1024\" src=\"https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-683x1024.jpg\" alt=\"\" class=\"wp-image-1631 size-full\" srcset=\"https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-683x1024.jpg 683w, https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-200x300.jpg 200w, https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-768x1152.jpg 768w, https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-1024x1536.jpg 1024w, https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw-1366x2048.jpg 1366w, https:\/\/en.nobomedicine.com\/wp-content\/uploads\/2023\/10\/Koh-Young-Il_bw.jpg 1707w\" sizes=\"auto, (max-width: 683px) 100vw, 683px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p>Youngil Koh, CEO, is the founder and oversees research and development essential for new drug development.<\/p>\n<p>He is also a professor in the Hematology-Oncology Department at Seoul National University Hospital and actively engages in collaborative research with various researchers and companies.<\/p>\n<p style=\"text-align: left;\"><strong>EDUCATION<\/strong><\/p>\n<ul style=\"list-style: inside; text-align: left;\">\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">PhD., Molecular and Clinical Oncology, Seoul National University, Korea<\/li>\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">Medical Doctor, Seoul National University College of Medicine, Korea<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: left;\"><strong>KEY PUBLICATION<\/strong><\/p>\n<ul style=\"list-style: inside; text-align: left;\">\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">30+ publications (Blood Cancer Journal, Hematologica, Nature Communications, etc.)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: left;\"><strong>CLINICAL TRIAL EXPERIENCE<\/strong><\/p>\n<p style=\"text-align: left;\">Conducted 40+ clinical trials<\/p>\n<ul style=\"list-style: inside;\">\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">An open\u2013label, multicenter, phase1 trial valuating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non-Hodgkin\u2019s lymphoma<\/li>\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">A Phase 1\/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) or Non-Hodgkin Lymphoma (NHL)<\/li>\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">A Modular Phase I\/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies<\/li>\n<li style=\"list-style-position: inside; text-indent: -20px; padding-left: 20px;\">A Phase I\/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)<\/li>\n<\/ul>\n<\/div><\/div>\n\n\n<h2>Youngil Koh, MD \/ PHD<\/h2>\n<h4><i>Co-Founder, Chief Executive Officer<\/i><\/h4>","protected":false},"featured_media":0,"parent":0,"template":"","class_list":["post-143","team","type-team","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/en.nobomedicine.com\/index.php?rest_route=\/wp\/v2\/team\/143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.nobomedicine.com\/index.php?rest_route=\/wp\/v2\/team"}],"about":[{"href":"https:\/\/en.nobomedicine.com\/index.php?rest_route=\/wp\/v2\/types\/team"}],"wp:attachment":[{"href":"https:\/\/en.nobomedicine.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}